Johnson & Johnson Reports Positive Phase 3 Results for ICOTYDE in Psoriatic Arthritis

Johnson & Johnson reported that its Phase 3 trial of oral peptide ICOTYDE (icotrokinra) met its primary endpoint in biologic-naïve adults with active psoriatic arthritis. At Week 16, 58% of treated patients achieved an ACR20 response, compared with 41% on placebo. Safety findings were consistent with the drug’s established profile, with no new safety signals reported.